Exploring the Relationship between Statins and Alzheimer’s Disease: Can Statins Really Prevent Alzheimer’s Disease?


Alzheimer’s Disease is a common form of dementia that has neurological and behavioral repercussions. It is definitively diagnosed usually via an autopsy when the following three common markers are found: flattened cortical gray matter, Tau proteins and Beta-amyloid proteins. Patients suffering from Down Syndrome or Parkinson’s Disease are often associated with Alzheimer’s because they have 2 of the 3 precursors. There has been extensive research on Alzheimer’s and many studies claim that statins, a cholesterol-reducing drug, can help prevent Alzheimer’s Disease resulting in low levels of beta-amyloid. However, there are several reasons to believe that this is not true and in some cases statins may even induce AD. This paper will examine the pathology of Alzheimer’s, the effect of statins and whether it truly plays a role in preventing AD.

Share and Cite:

Atta, M. (2015) Exploring the Relationship between Statins and Alzheimer’s Disease: Can Statins Really Prevent Alzheimer’s Disease?. Advances in Alzheimer's Disease, 4, 10-14. doi: 10.4236/aad.2015.41002.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Brookmeyer, R., Gray, S. and Kawas, C. (1998) Projections of Alzheimer’s Disease in the United States and the Public Health Impact of Delaying Onset. American Journal of Public Health, 88, 1337-1342.
[2] What Is Alzheimer’s? http://www.alz.org/alzheimers_disease_what_is_alzheimers.asp
[3] Glasser, S. (2013) Alzheimers. Neurology Course Lecture. American University of Antigua. Antigua, St. Johns.
[4] Hardy, J. and Allsop, D. (1991) Amyloid Deposition as the Central Event in the Aetiology of Alzheimer’s Disease. Trends in Pharmacological Sciences, 12, 383-388.
[5] Austen, B., Christodoulou, G. and Terry, J.E. (2002) Relation between Cholesterol Levels, Statins and Alzheimer’s Disease in the Human Population. Journal of Nutrition, Health & Aging, 6, 377-382.
[6] About Alzheimer’s Disease: Treatment. National Institute on Aging.
[7] Guo, W.S., Jiang, T.Z., Xing, X.N. and Cao, Y.P. (2013) A New DNA Vaccine Fused with the C3d-p28 Induces a Th2 Immune Response against Amyloid-Beta. Neural Regeneration Research, 8, 2581-2590.
[8] Ramirez, B., Blazquez, C., et al. (2005) Prevention of Alzheimer’s Disease Pathology by Cannabinoids: Neuroprotection Mediated by Blockade of Microglial Activation. Journal of Neuroscience, 25, 1904-1913.
[9] Buchman, A.S., Boyle, P.A., et al. (2012) Total Daily Physical Activity and the Risk of AD and Cognitive Decline in Older Adults. Official Journal of the American Academy of Neurology, 78, 1323-1329.
[10] Fonseca, A.C., Resende, R., Catarina, O. and Pereira, C. (2010) Cholesterol and Statins in Alzheimer’s Disease: Current Controversies. Experimental Neurology, 223, 282-293.
[11] Stancu, C. and Sima, A. (2001) Statins: Mechanism of Action and Effects. Journal of Cellular and Molecular Medicine, 5, 378-387.
[12] Wehrwein, P. (2011) Statin Use Is up, Cholesterol Levels Are down: Are Americans’ Hearts Benefiting? Harvard Health Publications.
[13] Alzheimer’s Facts and Figures. Alzheimer’s Association.
[14] Padala, K., Padala, P., McNeilly, D., Geske, J., Sullivan, D. and Potter, J. (2012) The Effect of HMG-CoA Reductase Inhibitors on Cognition in Patients with Alzheimer’s Dementia: A Prospective Withdrawal and Rechallenge Pilot Study. The American Journal of Geriatric Pharmacotherapy, 10, 296-302.
[15] Wagstaff, L., Mitton, M., Arvik, B.M. and Doraiswamy, P.M. (2003) Statin-Associated Memory Loss: Analysis of 60 Case Reports and Review of the Literature. Pharmacotherapy, 23, 871-880.
[16] Kivipelto, M., Helkala, E.L., Laasko, M.P., Haaninien, T., Alhainien, K., Soinenien, H., Tuomilehto, J. and Nissinen, A. (2001) Midlife Vascular Risk Factors and Alzheimer’s Disease in Later Life: Longitudinal, Population Based Study. British Medical Journal, 322, 1447-1451.
[17] Wood, W.G., Igbavboa, U., Eckert, G.P., Johnson-Anuna, L.N. and Müller, W.E. (2005) Is Hypercholesterolemia a Risk Factor for Alzheimer’s Disease? Molecular Neurobiology, 31, 185-192.
[18] Cunnane, S.C., Schneider, J.A., Tangney, C., Tremblay-Mercier, J., Fortier, M., Bennett, D.A. and Morris, M.C. (2012) Plasma and Brain Fatty Acid Profiles in Mild Cognitive Impairment and Alzheimer’s Disease. Journal of Alzheimer’s Disease, 29, 691-697.
[19] Mulder, M., Ravid, R., Swaab, D.F., de Kloet, E.R., Haasdijk, E.D., Julk, J., van der Boom, J.J. and Havekes, L.M. (1998) Reduced Levels of Cholesterol, Phospholipids, and Fatty Acids in Cerebrospinal Fluid of Alzheimer Disease Patients Are Not Related to Apolipoprotein E4. Alzheimer Disease and Associated Disorders, 12, 198-203. http://www.ncbi.nlm.nih.gov/pubmed/9772023
[20] Seneff, S. (2009) APOE-4: The Clue to Why Low Fat Diet and Statins May Cause Alzheimer’s.

Copyright © 2022 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.